(Lung Cancer) anti-PD-1 antibody + Chemotherapy Added as Neoadjuvant Therapy
(Lung Cancer) anti-PD-1 antibody + Chemotherapy Added as Neoadjuvant Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) anti-PD-1 antibody + Chemotherapy Added as Neoadjuvant Therapy
- April 5, 2023
- 1 min read
On March 27, 2023, Ono Pharmaceutical and Bristol-Myers Squibb jointly announced that they received approval for the additional indication of anti-PD-1 antibody for non-small cell lung cancer in combination with chemotherapy as neoadjuvant therapy.
This approval was based on the CheckMate-816 Phase III clinical trial, which enrolled patients with resectable stage I-IIIA non-small cell lung cancer. Patients were randomized into an anti-PD-1 antibody 300 mg + chemotherapy group and a chemotherapy group, both as neoadjuvant therapy. The endpoints included event-free survival, pathological complete response rate, and safety.
The trial results showed that the anti-PD-1 antibody + chemotherapy group demonstrated significant improvement in both event-free survival and pathological complete response rate compared with the chemotherapy group, and the adverse event profile was consistent with previous clinical trials.
anti-PD-1 antibody will serve as a new neoadjuvant therapy for non-small cell lung cancer patients, administered at 360 mg per dose in three-week treatment cycles for up to three cycles in combination with chemotherapy.
Source: https://www.ono-pharma.com/ja/news/20230327_2.html
-
Investigational drug
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.